Thermo Fisher Scientific and BioAnalytix Collaborate To Develop Advanced Biopharmaceutical Analysis Workflows
Collaboration aimed at developing new workflows to analyze highly complex biologic drugs such as monoclonal antibodies and biosimilars.
- (1888PressRelease) June 12, 2014 - SAN JOSE, Calif. - Scientists at Thermo Fisher Scientific and BioAnalytix, Inc., of Cambridge, MA, are combining their expertise to develop advanced analytical profiling platforms and applications to characterize biologic and biosimilar drugs.
Biologic drugs, such as therapeutic monoclonal antibodies, are extremely large and complex biomolecules, and represent one of the most significant areas in the pharmaceutical industry today. Minor differences in biologic structure from drug to drug, or from manufacturing lot to manufacturing lot, however, can profoundly affect these drugs' safety and efficacy profiles.
Sophisticated analytic workflows are therefore required to characterize the molecules accurately and ensure reproducible consistency during their development, scale-up and manufacturing processes. As respective leaders in analytic system performance and precise biologic analysis, Thermo Fisher and BioAnalytix are collaborating to develop advanced analytical profiling standards to support, enable and accelerate biologic and biosimilar drug development.
Under the collaboration, BioAnalytix's team of biologic drug experts will use Thermo Fisher Scientific's Orbitrap-based mass spectrometers, along with the company's sample preparation, separation/enrichment, standards, reagents and software to develop advanced applications.
"In partnership with top pharmaceutical companies and technology leaders like Thermo Fisher Scientific, it is our goal to establish and leverage leading analytical profiling standards in advancing the development, manufacture and regulatory approval of biologic and biosimilar drugs worldwide," said Kirt Poss, President and CEO of BioAnalytix.
"This is an exciting real-world opportunity to showcase the ability of our technologies to provide unique, critical insights into protein structures" said Ken Miller, vice president, marketing, for Thermo Fisher Scientific's life sciences mass spectrometry business. "We have a long history of successful collaboration with BioAnalytix scientists, and we look forward to continuing this productive relationship."
About BioAnalytix, Inc.
Located in Cambridge Massachusetts, BioAnalytix is a pharmaceutically oriented spin-out from the Barnett Institute of Chemical and Biological Analysis at Northeastern University. Founded in 2012 by thought leaders in biologic drug development, regulatory strategy, and advanced analytics, BioAnalytix works with leading pharmaceutical companies to develop and apply advanced analytic methods and data in enabling, improving and accelerating biologic therapeutics from development through market.
For more information, please visit www.bioanalytixinc.com.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $17 billion and 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our four premier brands - Thermo Scientific, Life Technologies, Fisher Scientific and Unity Lab Services - we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam